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Abstract 
BACKGROUND: There is controversy concerning the compared rates of decline of residual kidney function (RKF) 
in patients treated with continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD). 
OBJECTIVES AND METHOD: Following an observational, multicenter design, we studied 493 patients initiating 
peritoneal dialysis (PD) in four different Spanish units. We explored the effect of the PD modality on the rate of 
decline of RKF and the probability of anuria during follow-up. We applied logistic regression for intention-to-treat 
analyses, and linear mixed models to explore time-dependent variables, excluding those affected by indication bias. 
MAIN RESULTS: Patients started on APD were younger and less comorbid than those initiated on CAPD. Baseline 
RKF was similar in both groups (p = 0.50). Eighty-seven patients changed their PD modality during follow-up. The 
following variables predicted a faster decline of RKF: higher (rate of decline) or lower (anuria) baseline RKF, 
younger age, proteinuria, nonprimary PD, use of PD solutions rich in glucose degradation products, higher blood 
pressure, and suffering peritonitis or cardiovascular events during follow-up. Overall, APD was not associated with a 
fast decline of RKF, but stratified analysis disclosed that patients with lower baseline RKF had an increased risk for 
this outcome when treated with this technique (HR: 2.26, 95% CI: 1.09-4.82, p = 0.023). Moreover, the probability of 
anuria during follow-up was overtly higher in APD patients (HR: 3.22, 95% CI: 1.25-6.69, p = 0.002). 
CONCLUSIONS: Starting PD patients directly on APD is associated with a faster decline of RKF and a higher risk 
of developing anuria than doing so on CAPD. This detrimental effect is more marked in patients initiating PD with 
lower levels of RKF. 
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Introduction 
Preservation of residual kidney function (RKF) offers multiple benefits to patients undergoing chronic 
peritoneal dialysis (PD), including easier management of uremic toxicity and hypervolemia, better control 
of several complications of chronic kidney disease, less stringent dietary restrictions and improved quality 
of life (QoL). Moreover, both RKF at the initiation of PD and its time course correlate with survival of 
these patients [1].  
 
Many demographic and clinical factors have been claimed to influence the time course of RKF in PD 
patients [1]. Some of them (e.g. age) are not modifiable, but interventions on others may help to retard the 
natural decay of glomerular filtration rate (GFR). The latter comprise adequate control of blood pressure, 
reduction of proteinuria or avoidance of nephrotoxic drugs, among others. Some specific approaches have 
shown a beneficial effect for this purpose, including treatment with antagonists of the renin-angiotensin 
system (RAS) [2, 3] , use of PD solutions low in glucose degradation products (GDP) [4] or prevention of 
episodes of volume overload or dehydration [5, 6] . Finally, the roles of other factors, including glucose-
sparing PD regimes, the use of icodextrinbased solutions or efficient prevention of peritoneal infections 
remain unproven or controversial.  
 
The compared impact of continuous ambulatory PD (CAPD) and automated PD (APD) on the time 
course of RKF has been a recurrent matter of discussion since several studies, published in the late 1990s 
[7, 8], reported a faster decline of GFR in patients treated with the latter modality. Subsequently, several 
small randomized trials [9, 10] and observational studies [11] have provided controversial results. This 
question is consequential because a potential handicap of APD in this field could influence the current 
policy of many centers of starting patients directly on APD, according to their personal preference or to 
general QoL perceptions.  
 
We have undertaken a multicenter observational study to assess the role of a large group of 
demographic, clinical and dialysis-related variables on the time course of RKF (main outcome variable) 
in a population of incident patients on PD during a period of 11 years. Our primary focus was to disclose 
the compared impact of the modality of PD (study variable) on the main outcome variable.  
Method  
General Design  
Following a multicenter, observational design, we analyzed the risk profile for decline of RKF in a 
cohort of patients starting PD therapy in four Spanish centers during a period of 11 years (2000– 2010). 
The participating centers had in common accepted standards of quality and a large experience with APD, 
which was indicated as a starting modality essentially for patient’s preference and QoL reasons. 
Adequacy and ultrafiltration issues represented the most usual causes for later transfer from CAPD. APD 
was also recommended to facilitate management of some abdominal wall disorders in a small subset of 
patients, while fast small-solute peritoneal transport rates did not represent a sole indication for this 
technique in the participating centers.  
 
The main objective of the study was to disclose the role of the modality of PD (APD vs. CAPD; main 
study variable) on the time course of RKF (main dependent variable). Additionally, we performed 
analyses aimed to assess the role of other controversial factors on the outcome of RKF.  
 
The study complied with the requested ethical conditions for retrospective observational studies in the 
participating centers.  
  
Study Population  
We analyzed all patients starting PD in four different Spanish centers between January 2000 and 
December 2010 who fulfilled the following inclusion criteria:  
 
(1) Age older than 10 years  
(2) Minimum follow-up of 6 months on PD  
(3) Estimations of GFR at least at baseline and after 6 months on PD available  
(4) Baseline 24-hour urine volume ≥ 300 ml/24 h and GFR ≥ 1 ml/min  
(5) Clinical records available  
 
Table 1 displays the main baseline characteristics of patients, while table 2 depicts essential follow-up 
parameters. Data collection was closed on December 31, 2012.  
 
Patients were treated with standard PD systems (Baxter, Deerfield, Illinois; Fresenius, Bad Homburg, 
Germany). Icodextrinbased solutions were fully available in all centers during the recruitment and follow-
up periods. All centers followed accepted criteria for PD prescription. Dry-day APD was prescribed 
sporadically, and was not a subject of specific analysis.  
Table 1. Baseline demographic and clinical characteristics of participants 
 All CAPD APD p 
     
n  493 368 125  
Age, years  58.1±15.8 61.3±14.2 48.4±16.6 <0.001 
Gender (males/females)  63.7/36.3 64.0/36.0 62.9/37.1 0.83 
Kidney disease     0.20 
Glomerular  74 (15.0) 48 (13.0) 26 (21.0)  
Tubulointerstitial  51 (10.3) 40 (10.8) 11 (8.9)  
Vascular  52 (10.5) 40 (10.8) 12 (9.7) Cystic 
31 (6.3)  21 (5.7) 10 (8.1) Systemic 6 (1.2) 
3 (0.8)  3 (2.4) Diabetic nephropathy 144 (29.2) 113 (30.6) 
31 (25.0) Other/unknown 135 (27.4) 104 (28.2) 31 (25.0) 
Diabetes mellitus  189 (38.3) 145 (39.3) 44 (35.5) 0.52 
Body weight, kg  72.0±14.6 72.1±14.0 71.6±16.1 0.71 
BMI, kg/m2  26.8±4.8 27.0±4.8 26.1±4.8 0.10 
Origin     0.003 
Incident  454 (92.1) 343 (93.0) 111 (89.5)  
Hemodialysis  22 (4.5) 19 (5.1) 3 (2.4)  
Kidney transplant  17 (3.4) 7 (1.9) 10 (8.1)  
Charlson’s score  4.3±2.2 4.5±2.3 3. 8±1.8 <0.001 
Systolic blood pressure, mm Hg  136±20 136±19 135±18 0.53 
Diastolic blood pressure, mm Hg  77±12 76±11 80±12 <0.001 
Mean blood pressure, mm Hg  99±12 96±12 99±12 0.046 
Hemoglobin, g/dl  11.3±1.6 11.3±1.5 11.3±1.7 0.88 
Albumin, g/l  36.5±5.3 36.5±5.3 36.7±5.4 0.66 
Cholesterol, mg/dl  174.4±50.3 169.8±43.6 188.2±64.7 0.002 
C-reactive protein, mg/dl  0.50 (0.0/17.8) 0.59 (0.0/17.8) 0.40 (0.01/6.40) 0.002 
GFR, ml/min  7.5±3.3 7.5±3.4 7.4±3.2 0.50 
Diuresis, ml/24 h  1,437±665 1,418±654 1,495±696 0.26 
Proteinuria, mg/24 h  1,733±2,379 1,695±2,557 1,947±1,795 0.54 
D/P creatinine 240 min (PET)  0.66±0.13 0.66±0.12 0.68±0.15 0.027 
     
 
Values represent means ± SD or n (%), except C-reactive protein (median with range). Comparisons by Student’s t test, Mann-
Whitney and χ2 distribution. D/P = Dialysate-to-plasma ratio; PET = peritoneal equilibration test. 
 
 
  
Table 2. Prescription and clinical variables during follow-up 
 
Baseline  
(n = 493) 
6 months  
(n = 493) 
12 months  
(n = 419) 
24 months  
(n = 287) 
     
Modality of PD (% APD)  125 (25.2) 161 (34.3) 161 (38.4) 120 (42.0) 
Number of exchanges (24 h)  3.5±3.0 3.7±3.0 3.8±4.0 4.1±4.0 
Total volume infused, l/24 h  6.9±2.1 7.4±2.4 7.8±2.7 8.5±3.0 
Peritoneal glucose load, g/24 h  90±39 97±48 102±53 114±61 
Icodextrin  287 (58.6) 308 (65.7) 283 (67.9) 197 (69.9) 
Low-GDP solution  187 (38.2) 177 (37.6) 155 (37.0) 113 (39.9) 
Number of antihypertensives  1.7±1.1 1.7±1.2 1.7±1.2 1.6±1.2 
RAS antagonists  222 (45.3) 212 (44.9) 189 (46.0) 125 (44.0) 
Dose of furosemide, mg/24 h 37.1±44.6 62.7±60.8 72.0±66.6 70.4±68.9 
Systolic blood pressure, mm Hg  136±19 134±19 133±18 132±18 
Diastolic blood pressure, mm Hg  77±12 76±11 75±11 74±10 
D/P creatinine 240 min (PET)  0.66±0.13 – 0.67±0.12 0.66±0.13 
Ultrafiltration, ml/24 h  888±778 982±655 1,040±626 1,118±632 
Proteinuria, g/24 h  1.7±2.4 – 1.0±1.3 0.8±1.1 
     
 
Figures denote means ± SD and n (%) (categorical). Values in bold represent significant difference vs. baseline. D/P = Dialysate-
toplasma ratio; PET = peritoneal equilibration test. 
Study Variables  
RKF was estimated from the mean of urea and creatinine clearances in 24-hour urine collections 
(GFR) at baseline, and then after 6, 12 and 24 months of follow-up. The main study variable was the 
modality of PD at the start of the second month of dialysis. This approach was undertaken because in 
some of the participating centers, APD patients are kept on CAPD for some weeks to permit 
familiarization with the latter technique. No patient was switched from CAPD to APD during the first 
month due to inadequacy of PD or decline of RKF. We also explored the role of selected variables on the 
time course of GFR, including blood pressure levels (clinical records), antihypertensive drugs and 
diuretics, use of RAS antagonists, proteinuria, use of PD solutions based on icodextrin or low in GDP, 
and the influence of cardiovascular (CV) events (demanding hospital admission) and peritoneal infections 
during the follow-up period for GFR (secondary study variables).  
 
Control variables included common demographic, clinical, biochemical and prescription variables 
(tables 1, 2). Hemoglobin, albumin, cholesterol, urea and creatinine levels were estimated with the help of 
autoanalyzers. C-reactive protein levels were estimated by immunoturbidimetry, and 24-hour proteinuria 
was estimated according to colorimetric methods.  
Strategy of Analysis and Statistics  
Numerical variables are presented as means ± SD, unless there was markedly abnormal distribution 
(median with range). Categorical variables are presented as n (%). Univariate comparisons were produced 
according to Student’s t test, ANOVA, Mann-Whitney (numerical) and χ2 distribution (categorical) 
analyses.  
 
During a preliminary analysis, we disclosed that age was the only variable showing an independent 
association with PD modality selection (probability of APD selection: 0.94 per year, 95% CI: 0.93–0.96, 
p < 0.0005). For this reason, age was a control variable in all multivariate analyses comparing CAPD and 
APD.  
  
The distribution of GFR was not normal, and linear regression models could not be applied due to a 
markedly abnormal distribution of residuals (Kolmogorov-Smirnov). This anomaly could not be corrected 
by logarithmic or other usual transformations. Consequently, we applied logistic regression for 
multivariate analyses concerning baseline variables (intention-to-treat approach), using as dependent 
variables a rate of decline of GFR above or below median values, and the probability of complete loss of 
GFR (anuria, defined by 24-hour urine volume diuresis <100 ml/24 h or GFR ≤ 0.2 ml/min) during 
follow-up. CV events and peritoneal infections during the follow-up period were managed as binary, non-
time-dependent factors during this phase. Median values of GFR decay were estimated for the period of 
follow-up of each subgroup of individuals because the decline of RKF was not linear (faster during the 
first year). We performed a general survey of interactions and stratified analyses, focusing on the baseline 
modality of PD.  
 
Longitudinal analysis (as-treated approach) was carried out using linear mixed models with forward 
stepwise variable selection to estimate the effect of time-dependent variables on the evolution of GFR. 
Patient effect was adjusted as a random effect, while the covariates were adjusted as fixed effects. 
Associations between the variables studied and GFR were evaluated using beta coefficients, with 95% CI, 
in the fixed-effects part of the models. All the secondary study variables were scrutinized under this 
strategy. Time-dependent associations between the modality of PD and other conditions of prescription 
on one side, and the time course of GFR on the other, were explored, but not considered for final analyses 
due to the likelihood of bias by indication (switch to APD and increasing prescription conditions more 
likely in patients with a faster decline of GFR). This presumed bias was confirmed by analysis of the 
compared characteristics of patients started on CAPD, according to later change to APD. Patients 
changing to APD displayed a similar baseline RKF (7.3 ± 3.8 vs. 7.6 ± 3.4 ml/min, p = 0.51), but suffered 
a faster decline during the first 6 months of follow-up (0.18 ± 0.39 vs. 0.05 ± 0.50 ml/min/month, p = 
0.027) and presented lower levels of GFR at the end of this period (6.2 ± 3.0 vs. 7.4 ± 3.8 ml/ min, p = 
0.013) than patients who continued on CAPD.  
 
We used SPSS 19.0 and Stata v.10 software for data management.  
Results  
Overview  
Four hundred and ninety-three patients were studied, and 287 completed the scheduled maximal 
follow-up period of 24 months (tables 1, 2). Patients treated in different hospitals shared similar rates of 
decline of GFR (p = 0.56, ANOVA), although patients from one center (UHPR) initiated PD with a 
moderately lower GFR than the other three (6.8 ± 3.6 ml/min, p = 0.026).  
 
Most variations from baseline were related to the natural decay of GFR and changes in the conditions 
of prescription of PD (table 2). Eighty-seven patients changed their PD modality during follow-up, with 
81 of them switching from CAPD to APD (66 during the first year, and 15 during the second year). 
Patients treated with CAPD and APD made a similar use of icodextrin at inception (57.2 vs. 62.6%, 
respectively, p = 0.29), but there was a consistent trend to a higher use of this type of solution in APD 
patients, which was observable after the sixth month (61.0 vs. 74.5%, p = 0.003). However, low GDP 
solutions were used more frequently in CAPD patients after baseline (41.5 vs. 28.2%, p = 0.008). Similar 
proportions of CAPD and APD patients were treated with RAS antagonists at baseline and during follow-
up.  
 
Eighty-seven patients (18.0%) experienced at least one CV event during follow-up, occurring 12.0 ± 
6.6 months after inception of PD. The main CV events included heart failure (26.2%), peripheral 
revascularization or amputation (23.6%), coronary events (21.0%), and stroke (10.0%). On the other 
hand, 188 patients (38.5%) experienced at least one episode of peritonitis, starting 7.8 ± 5.8 months after 
initiation of PD.   
Univariate Analysis  
Univariate analyses disclosed an association between a faster rate of decline of GFR and the following 
variables: kidney disease other than interstitial nephropathy (p = 0.022), diabetes mellitus (p = 0.046), 
origin other than primary incidence on PD (p = 0.023), higher systolic (p = 0.056) and diastolic (p = 0.01) 
blood pressure levels, number of antihypertensive drugs prescribed (p = 0.02), higher C-reactive protein 
levels (p = 0.035), higher GFR (p < 0.0005) and 24-hour urine volume diuresis (p = 0.003) at the start of 
PD, and heavier proteinuria (p = 0.003; other variables not significant). The crude rates of decline of GFR 
were similar in patients started on CAPD (0.13 ± 0.25 ml/min/month) and APD (0.15 ± 0.20, p = 0.41). 
Univariate correlates of the development of anuria during follow-up are presented in table 3. Figure 1 a, b 
depicts the time course of GFR and diuresis, respectively, according to the baseline modality of PD.  
Table 3. Probability of anuria during follow-up according to baseline variables 
 Univariate  
p 
 anuria (n = 44) no anuria (n = 449)  
     
Gender, % males  43.2 65.7  0.003 
Cholesterol, mg/dl  195.7±72.1 172.4±47.4  0.046 
GFR, ml/min  5.5±3.3 7.7±3.3  <0.001 
24-hour urine volume, ml  1,006.1±553.4 1,479.5±661.0  <0.001 
Origin other than primary, %  26.5 5.1  <0.001 
Total volume infused, ml/24 h  7,797.7±2,578.5 6,821.4±1,981.7  0.018 
Number of exchanges per day  4.1±0.9 3.5±0.8  <0.001 
Peritoneal glucose load, g/24 h  111.8±47.6 87.5±36.8  <0.001 
APD as initial modality, %  50.0 22.7  <0.001 
CV event during follow-up, %  30.2 16.8  0.028 
Peritonitis during follow-up, %  55.8 36.9  0.015 
     
 
Only variables presenting significant differences. 
 
 
 
 
Fig. 1. a Time course of RKF (mean renal clearance) according to baseline modality of PD. b Evolution of 24-hour urine volume 
according to baseline modality of PD. Values denote means with SD. 
  
Multivariate Analysis Relating Baseline Variables with the Rate of Decline of GFR 
Table 4 depicts the variables showing an independent association (or trend) with a faster-than-median 
rate of decline of GFR. Higher baseline GFR, younger age and proteinuria were most consistently 
associated with a fast decline of GFR. PD after hemodialysis or transplant failure, poor control of blood 
pressure, and use of icodextrin for the long dwell were also associated with a relatively fast decay of 
GFR. Secondary analyses disclosed first-degree interaction terms between baseline GFR on one side and 
mean blood pressure (p = 0.001) or the modality of PD (p = 0.008) on the other.  
Table 4. Decline of GFR during follow-up 
 Multivariate  p 
 OR 95 % CI   
     
Baseline GFR (× ml/min)  1.29 1.19–1.38  <0.001 
Age (× year)  0.98 0.97–0.99  0.005 
Origin other than incident  2.68 1.29–6.13  0.019 
Baseline proteinuria (× g/24 h)  1.25 1.10–1.43  0.001 
Baseline mean blood pressure (× mm Hg)  1.02 1.01–1.04  0.054 
Baseline number of antihypertensives  1.21 1.01–1.48  0.048 
CV event during follow-up  2.27 1.29–4.02  0.005 
Baseline icodextrin  0.67 0.44–1.02  0.062 
APD starting modality     
All  1.06 0 .65–1.71  0.83 
Baseline GFR >7.5 ml/min  0.64 0.34–1.20  0.16 
Baseline GFR ≤7.5 ml/min  2.26 1.09–4.82  0.023 
     
 
Logistic regression analysis. Dependent variable: decline of GFR above median value (corrected for follow-up). 
Remarkably, the modality of PD did not appear to bear any overall influence on the time course of 
GFR. However, interaction term-oriented stratified analysis confirmed that for patients starting PD with a 
below-median GFR, APD was associated with a significantly faster decline of GFR, which was not 
observed for patients starting with above-median GFR levels (table 4).  
Multivariate Analysis Relating Baseline Variables with the Probability of Anuria during Follow-Up 
Table 5 displays the variables independently associated with a higher risk of complete loss of RKF 
during follow-up. Again, baseline GFR was a strong predictor of this outcome, but in this case the 
correlation was inverse, indicating that starting PD with a lower level of GFR increased the probability of 
anuria. Nonprimary PD and the development of a CV event during follow up also portended a higher risk 
of anuria. Finally, APD was associated with a significant risk of anuria in the whole sample. Similarly to 
the previous case, the compared risk with CAPD was higher in patients initiating PD with lower levels of 
GFR, although in this case the difference between both groups was less marked, and the corresponding 
interaction term did not reach statistical significance.  
 
  
Table 5. Probability of anuria during follow-up according to baseline variables 
 Multivariate  
p 
 OR 95% CI  
     
Baseline GFR (× ml/min)  0.80 0.70–0.89  <0.001 
Age (× year)  0.99 0.97–1.00  0.19 
Origin other than incident  3.05 1.30–7.20  0.011 
CV event during follow-up  2.42 1.10–5.37  0.029 
APD starting modality     
All  3.22 1.55–6.69  0.002 
Initial GFR >7.5 ml/min  1.28 0.32–5.11  0.72 
Initial GFR ≤7.5 ml/min  4.28 1.90–10.28  0.001 
     
 
Time-Dependent, Multivariate Analysis of GFR  
Mixed models confirmed the expected associations between the natural decay of GFR on one side, 
and the conditions of prescription (total dialysate volume and number of exchanges per 24 h, peritoneal 
glucose load, daily ultrafiltration), including the modality of PD (B = –0.857, 95% CI: –1.265/–0.449, p < 
0.001), on the other (other data not presented). Table 6 shows the results focused on time-dependent 
variables with a lower risk of bias by indication for the time course of GFR. Both peritoneal infection and 
CV events during follow-up showed a consistent association with the rate of decline of GFR. In addition, 
the use of low-GDP solutions showed an apparent protective effect on GFR in this model. However, we 
could not demonstrate an association between the time course of RKF and other variables, including 
blood pressure levels or the use of RAS antagonists or icodextrin- based solutions.  
Table 6. Mixed model analysis to assess the effect of time-dependent variables on the rhythm of decline of GFR 
Variable  Coefficient EE p 95% CI 
     
Time: 6 months  –0.536 0.134 <0.001 –0.798/–0.274 
Time: 12 months  –1.637 0.143 <0.001 –1.917/–1.357 
Time: 24 months  –2.649 0.164 <0.001 –2.971/–2.327 
Event: CV  –0.812 0.388 0.036 –1.573/–0.052 
Event: peritonitis  –1.039 0.307 0.001 –1.641/–0.438 
RAS antagonists (ref. No)  0.004 0.202 0.984 –0.393/0.401 
Mean blood pressure  0.006 0.004 0.167 –0.002/0.014 
Low GDP PD solutions  1.177 0.398 0.003 0.397/1.957 
Constant  7.298 0.667 <0.001 5.990/8.606 
     
Random effects parameters  Estimator EE p 95% CI 
     
   <0.001  
Var. (_cons)  8.783 0.664  7.574/10/185 
Var. (residual)  3.944 0.168  3.628/4.288 
     
 
Dependent variable: GFR. Negative coefficients denote a detrimental effect, and positive coefficients denote 
a positive effect on the time course of GFR. AIC: 7,686.126; BIC: 7,766.613. 
 
 
  
Discussion  
The results of the present study give support to the concern for a detrimental effect of APD on the 
time course of RKF. This question has been a recurrent matter of controversy [11] since first raised in the 
second half of the 1990s [7, 8], with some observational studies disclosing differences [12, 13] which 
other investigations have been unable to detect [14–17]. There are several potential explanations for these 
discrepancies. The first is the paucity and small size of randomized studies addressing this question [9, 
10]. A majority of the cohort studies were also small, and clearly underpowered to detect differences. 
This problem has often been aggravated by imbalances between the compared groups (most patients on 
CAPD, few on APD). In addition, observational studies suffer a permanent risk of methodological biases. 
For instance, PD registries may show similar demographic characteristics for CAPD and APD patients at 
large [13, 18], but in practice the criteria for assignment of the modality of PD may not be equilibrated. 
For example, individual preference and QoL issues may encourage the use of APD in younger and 
healthier patients, who enjoy an active lifestyle. Conversely, APD is a common choice for older patients 
in countries which provide assisted PD [19].  
 
RKF may also influence the selection of the modality of PD. Thus, in centers which emphasize 
indication for adequacy reasons, patients with lower levels and faster rates of decline of RKF may be 
overassigned to APD. On the other hand, many patients switch their initial PD modality during follow-up 
(most commonly CAPD to APD), further complicating data analyses. Time-dependent approaches could 
compensate for this problem but are difficult to apply, due to the risk of bias by indication, because 
transfer from CAPD to APD is often undertaken when RKF declines and more intensive prescriptions are 
needed. Overall, the possibility that patients prone to a rapid decline of RKF are treated with APD rather 
than with CAPD, either since inception or during follow-up, is always present in cohort studies, and must 
be addressed with particular care during statistical analyses.  
 
There are other possible reasons for the above-mentioned discrepancies, including the variability of 
the strategies of prescription of APD. For instance, the choice of intensive versus incremental prescription 
policies, as well as the variable use of intermittent (dry-day) APD, may explain some differences among 
studies. Finally, the particularities of the dependent variable (rate of decline of RKF) may represent 
another issue. First, RKF has been estimated using different methods, which may not be equivalent. In 
addition, the decline of RKF is not linear, which complicates statistical analyses.  
 
The reasons why RKF should decline faster during APD than during CAPD therapy are also 
controversial, but some claimed hemodynamic effects of the former technique could help to explain the 
difference. APD uses higher fill volumes than CAPD, and the conditions of prescription (frequent short 
cycles, more intensive ultrafiltration) during the night session are relatively aggressive. These two factors 
have been shown to result in hemodynamic disturbances, including significant oscillations in cardiac 
output and peripheral resistance [20, 21]. These changes may accelerate the decay of RKF. On the other 
hand, more intensive APD schedules associate significant peritoneal glucose loads [22], which may 
impact negatively on RKF, either through generation of GDP [23] or indirectly by worsening metabolic 
disease. Remarkably, the peritoneal glucose load at the start of PD was not a consistent predictor of the 
decline of RKF in our study.  
 
According to our results, patients started directly on APD underwent a faster decline of RKF than 
those treated with CAPD. This effect was overt when we explored the risk of anuria during follow-up 
(table 5). On the other hand, the rate of decline of RKF was not globally different between CAPD and 
APD patients (table 4), but APD was also clearly detrimental for RKF in the subset of patients started on 
PD with lower levels of GFR. The reasons for the latter finding are not totally clear, but we suggest that 
this subgroup of patients demanded more aggressive ultrafiltration and higher peritoneal glucose loads, a 
setting in which APD could be particularly harmful. A recent study [13] observed a time-dependent 
interaction between baseline GFR and the modality of PD. During the first year of follow-up, patients 
with a higher baseline GFR did significantly worse under APD than under CAPD therapy. However, 
during the second and third years, an opposite trend was observed although, in the latter case, the 
difference was not statistically significant.   
Our analysis confirms previous reports showing younger age, poor blood pressure control or heavier 
proteinuria at the start of PD is associated with a fast decline of RKF [1]. In addition, patients initiating 
PD after hemodialysis and, particularly, after failure of a kidney transplant also suffered a relatively rapid 
loss of RKF (tables 4, 5) [24, 25]. Icodextrin showed a marginal protective effect on the time course of 
RKF, but the association did not reach statistical significance (table 4). On the other hand, the results of 
time-dependent analysis (table 6) suggest that low-GDP solutions may protect RKF, in agreement with 
several previous reports [4]. Moreover, clinical events (peritonitis, CV events) during follow-up had a 
clear impact on the time course of RKF. Peritonitis has previously been reported to influence RKF 
negatively [15, 17]. Regarding CV events, episodes of heart failure have been most commonly claimed to 
be harmful to RKF [5, 26]. However, we did not detect any beneficial effect of treatment with RAS 
antagonists on RKF. At least two small randomized studies have detected such an effect [2, 3], but a 
recent observational study also has not observed this [13].  
 
The main limitation of our study is its observational, nonrandomized design, which demands specific 
strategies to overcome potential biases. The study population was relatively large, but may still have been 
insufficient to categorize some effects. Among its strengths, clinical records were rather complete, 
permitting analysis of the most important variables. The multicentric strategy also improved the quality of 
the study. Importantly, the distribution of patients between the study groups was more balanced than in 
any previous study, allowing more stable and reliable estimations.  
 
In summary, starting PD therapy by APD may be associated with a faster decline of RKF and a higher 
probability of developing anuria during follow-up than doing so with CAPD. This handicap is apparently 
restricted to patients who initiate treatment with relatively low levels of RKF. These findings should be 
taken into consideration at the time of selecting the modality of PD in patients starting this therapy. Other 
factors which correlate independently with a relatively rapid decay of RKF include younger age, marked 
proteinuria, poor control of blood pressure and origin other than primary incidence of PD. Time-
dependent analyses also indicate that the use of conventional rather than low-GDP solutions and suffering 
peritoneal infections or significant CV events during follow-up also portend a faster decline of RKF. 
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